Omeros (OMER) vs Oric Pharmaceuticals (ORIC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 322.3% versus a loss of 14.9%. Over five years, OMER leads with a +142.6% price change compared with -26.0% for ORIC. Omeros is the larger company by market cap ($1.36 billion vs $1.24 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | ORIC |
|---|---|---|
| Share price | $18.75 | $12.01 |
| Market cap | $1.36B | $1.24B |
| 1-day change | +1.30% | +0.25% |
| YTD return | +9.14% | +46.82% |
| 1-year return | +322.30% | -14.94% |
| 5-year return | +142.56% | -26.00% |
| P/E ratio (TTM) | 15.37 | — |
| Forward P/E | 15.24 | — |
| EPS (TTM) | $1.22 | $-1.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.24 | $14.68 |
| 52-week low | $4.06 | $7.23 |
| Distance from 52-week high | -11.72% | -18.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.67% | +78.43% |
| Average volume | 1.75M | 1.47M |
| Shares outstanding | 72.39M | 103.65M |
| Employees | 175 | 111 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed ORIC by 337.2 percentage points over the past year.
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Oric Pharmaceuticals
ORIC stock →ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees
OMER vs ORIC FAQ
Which is bigger, Omeros or Oric Pharmaceuticals?
Omeros (OMER) is larger, with a market capitalization of $1.36B compared with $1.24B for Oric Pharmaceuticals (ORIC).
Which stock has performed better over the past year, OMER or ORIC?
OMER returned +322.30% over the past 12 months, compared with -14.94% for ORIC (price return, excluding dividends). Past performance does not predict future results.
Are Omeros and Oric Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.